Drugs / Cetuximab-IRDye800
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05929456 | May 2023 → Oct 2024 | glioblastoma | University Medical Center Groningen | Unknown | No outcome recorded |
| Phase 1 | NCT05376202 | Mar 2022 → May 2023 | squamous cell carcinoma of penis | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 1 | NCT04638036 | Nov 2020 → Jan 2022 | rectal cancer | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 1 | NCT04161560 | Nov 2019 → Nov 2020 | — | Fifth Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 1 | NCT01987375 | Nov 2015 → Apr 2017 | head and neck cancer | Eben Rosenthal | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03134846 | Dec 2017 → Dec 2021 | head and neck squamous cell carcinoma | University Medical Center Groningen | Unknown | No outcome recorded |
| Phase 1/2 | NCT02855086 | Oct → Nov 2016 | brain neoplasm, malignant glioma | Eben Rosenthal | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06101394 | Jan 2024 → Jul 2025 | lung cancer | University of Turin, Italy | Unknown | No outcome recorded |
| Phase 2 | NCT05499065 | Mar 2023 → Oct 2024 | head and neck squamous cell carcinoma | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 2 | NCT02736578 | Jul 2016 → Apr 2017 | pancreatic adenocarcinoma | Eben Rosenthal | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cetuximab-IRDye800 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04161560 ↗ |
| Known as | cetuximab-800CW | “Administrate 75mg cetuximab + 15mg cetuximab-800CW for fluorescence visualization” NCT05499065 ↗ |
| Known as | Cetuximab-IRDye800CW | “Sensitivity and Specificity of Cetuximab-IRDye800CW to Identify Regional Metastatic Disease in Head and Neck Cancer.” PMID 28446503 ↗ Apr 2017 |
| Action | Inhibit | “inhibit and degrade the EGFR” NCT06101394 ↗ |
| Modality | Monoclonal antibody | “Florescent Imaging Cetuximab is a chimeric (mouse/human) monoclonal antibody that targets the epidermal growth factor (EGF) receptor (EGFR). EGFR is highly-expressed in...” NCT02736578 ↗ |
| Route | Intravenous | “three escalating dose levels of intravenous infusion of cetuximab-IRDye800” NCT01987375 ↗ |
| Target | EGFR | “Florescent Imaging Cetuximab is a chimeric (mouse/human) monoclonal antibody that targets the epidermal growth factor (EGF) receptor (EGFR).” NCT02736578 ↗ |